Dual EGFR and MEK and/or mTOR inhibitors showed improved response in tumor models harboring aberrant biomarkers, such as RAS, BRAF and PIK3CA mutations [119, 120, 122, 123], suggesting that they might prevent the activation of resistance pathways. Here, EGFR is linked to neoplasm.